SEC Form 4 · accession 0001012975-15-000431
Sage Therapeutics, Inc. · SAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Nelsen
Director · 10% Owner
Period of report
May 28, 2015
Accepted (ET)
Jun 1, 2015 · 4:31 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597553
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $73.13 | May 28, 2015 | A | 13,922 | A | — | May 28, 2025 | Common Stock | 13,922 | 13,922 | D |
Explanation of responses
- F1The stock option award was issued pursuant to the Sage Therapeutics, Inc., 2014 Stock Option and Incentive Plan. The option shall vest in full on May 28, 2016, subject to continued service through such date.